Patent Oppositions in cancer drugs industry

Explore the competitive field of cancer drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in cancer drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the cancer drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the cancer drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Binding Molecules For Bcma And Cd3AMGENAug 26, 2026REGENERON PHARMACEUTICALS
Combination Comprising An Mek Inhibitor And A B-Raf InhibitorNOVARTISAug 26, 2026HAMM&WITTKOPP PATENTANWÄLTE PARTMBB
Improved Method For Producing Antibody-Drug ConjugateDAIICHI SANKYOAug 25, 2026SANDOZ
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 19, 2026WITHERS & ROGERS
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHMEAug 17, 2026WUESTHOFF & WUESTHOFF
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 17, 2026LUMARA BIO ONCOLOGICS
Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]UreaPFIZERAug 16, 2026ELKINGTON AND FIFE
Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)BenzamideACERTA PHARMAAug 11, 2026HAMM&WITTKOPP PATENTANWÄLTE PARTMBB
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEONE MEDICINES IAug 5, 2026EGIS
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEIGENEAug 4, 2026DEVA HOLDING

To stay ahead in the competitive cancer drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the cancer drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Apr 14, 2021Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY24
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI15
Jan 7, 2026Formulations Of EnzalutamideASTELLAS PHARMA11
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTIS10
Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS10
Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI10
Oct 26, 2016Use Of Anti-Vegf Antibody In Combination With Chemotherapy For Treating Breast CancerF HOFFMANN LA ROCHE10
Oct 29, 2025Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBB10